Purpose: To compare long-term survival in patients with locally advanced and metastatic transitional cell carcinoma (TCC) of the urothelium treated with gemcitabine plus cisplatin (GC) or methotrexate/vinblastine/doxorubicin/cisplatin (MVAC).
introduction
Combination chemotherapy is the treatment of choice for patients with inoperable locally-advanced or metastatic bladder cancer. Based in part on superior results in phase III studies, MVAC is a frequently used regimen for this disease [1] [2] [3] [4] . However, MVAC is associated with significant toxicities and a toxic death rate of 3-4% [2, 3] . Thus, there is a need for other regimes that provide better survival outcome or similar survival with reduced toxicity.
Based on encouraging phase II results with gemcitabine and cisplatin in bladder cancer [5] , a multinational, multicenter, randomized phase III study was performed to compare overall survival between GC-and MVAC-treated patients with locally advanced and metastatic transitional cell carcinoma (TCC) of the urothelium [6] 405 patients were recruited. This study showed similar efficacy with regard to overall survival (GC 13.8 months, MVAC 14.8 months), time to progressive disease (GC 7.4 months, MVAC 7.4 months), and response rate (GC 49.4%, MVAC 45.7%) but a better safety profile for GC with the most important toxicity differences being significantly less: febrile neutropenia, neutropenic sepsis, and mucositis. A recent costutility analysis of the GC versus MVAC regimens concluded that GC offered reasonable value in this disease setting [7] . The detailed results of the GC versus MVAC study have been reported [6] and led to the widespread adoption of the GC combination in more than 60 countries. However, the median follow up of the patients in this study was only 19 months, and questions remained regarding the long-term efficacy of the GC combination, especially compared to MVAC. An updated analysis of overall survival and other time-to-event endpoints was therefore performed five years after the last patient was enrolled into the study. As in the initial publication, univariate analysis of pre-specified prognostic factors were investigated the influence of other identified factors was explored in a multivariate analysis on overall and progression-free survival. Safety results were not updated, since the vast majority of patients had already completed their chemotherapy at the time of the first survival analysis, and therefore, no changes were to be expected from a new analysis.
patients and methods

eligibility criteria
patients. The details of the study have been reported in detail [6] . Eligible patients had measurable or evaluable, histologically proven locally advanced (T4b, N2, N3) or metastatic (M1) TCC of the urothelium. Prior immunotherapy or chemotherapy was not allowed. Prior local intravesical, radiation, or immunotherapy was permitted if completed at least 4 weeks before enrollment. Eligible patients were required to have Karnofsky performance status (PS) ‡70, adequate bone marrow reserve (white blood cell [WBC] count ‡3.5 · 10 9 /l, platelets ‡100 · 10 9 /l, and haemoglobin ‡10 g/dl) and renal function (measured creatinine clearance ‡60 ml/min), and an estimated life expectancy of at least 12 weeks. This study was conducted according to the ethical principles of the Declaration of Helsinki, the applicable guidelines for good clinical practice (GCP), or the applicable laws and regulations of the countries in which the study was conducted, whichever offered the greater protection of the individual. Written informed consent was obtained from all patients before randomization.
study design and treatment evaluation
Patients were randomized to receive either GC or MVAC in this phase III, active controlled, open label, randomized study. The Pocock and Simon minimization method was used to perform treatment allocation by the Netherlands Cancer Institute [8] /l and platelets were ‡100 · 10 9 /l. If a cycle was delayed for more than 4 weeks, patients were taken off the study. On the GC arm, gemcitabine doses on day 8 or 15 were omitted for WBC £1.99 · 10 /l. Dose was adjusted for nonhematologic toxicity, including mucositis on both study arms. Patients received a maximum of six cycles of treatment unless they progressed or developed unacceptable toxicity or the patient, attending physician, or sponsor requested discontinuation.
Supportive care could include blood transfusions and the administration of antiemetics and analgesics, as appropriate. In the absence of disease progression, palliative radiotherapy was allowed for pre-existing, painful bony lesions. Prophylactic use of growth factors such as filgrastim was not recommended in either arm. No other antineoplastic therapy was permitted.
Blood counts and serum chemistries were performed weekly and creatinine clearance was calculated before chemotherapy administration. Performance status was assessed before each cycle and weight was measured weekly. Tumors were assessed using WHO criteria, radiologically and by physical examination. Tumors were reassessed every two cycles and responses were confirmed after at least 4 weeks.
Overall survival was measured from the date of randomization until death. Patients who had not died or who were lost to follow up were censored for overall survival when they were last known to be alive. Progression-free survival was measured from the date of randomization until death or progression. Patients who were alive and who had not progressed or were lost to follow-up were censored for progression free survival at the date that they were last known to be alive and progression free.
statistical considerations
The Kaplan-Meier method was used to calculate time-to-event endpoints, and they were compared using the log-rank and Wilcoxon tests. For both endpoints, the 5-year survival rate was computed for each treatment arm using the Kaplan-Meier method and compared based on a normal approximation for the difference between the rates. Cox's proportional hazards model was used to examine the effects of pre-specified baseline prognostic factors including performance status, TNM stage, presence of visceral metastases, alkaline phosphatase level, number of sites of disease, prior radiotherapy, disease measurability, age, gender, and time to diagnosis. Wald's test was used to calculate P values. Factors that showed individual prognostic value in univariate models were used to examine their joint prognostic value in a multivariate model. A final model was developed using a backward selection strategy. Treatment was added to the final model to assess its effect when adjusted for the presence of important prognostic factors.
results
Between November 1996 and September 1998, 426 patients entered the study. 405 patients were randomized, 203 to the GC arm and 202 to the MVAC arm. Nineteen patients did not meet protocol entry criteria, one died from bladder cancer before randomization, and one did not continue due to personal reasons.
patient characteristics
Patient characteristics were generally well balanced across treatment arms (Table 1) . However, more patients on GC had adverse prognostic factors compared to the MVAC arm: visceral metastases (GC 49% versus MVAC 46%) and M1 disease regardless of T or N status (GC 69% versus MVAC 63%) although these differences were not statistically significant. A higher percentage of patients on the GC arm had four or more sites of disease (GC 21% versus MVAC 17%).
long-term overall survival
At the time of our initial analysis [6] Survival rates at 24 months, 48 months, and 60 months were 25.0%, 16.4%, and 13.0%, respectively on GC and 31.0%, 17.3%, and 15.3%, respectively on MVAC (Table 2 ). Figure 1 provides survival curves for each treatment arm. Univariate analyses were performed on prognostic groups based on several pre-specified factors including performance status and visceral metastases (Table 3) . A multivariate analysis of all significant prognostic factors was conducted using backward selection to determine the final model. Independent prognostic factors adversely affecting overall survival were performance status (70), TNM staging (M 1 ), high alkaline phosphatase expression, number of sites of disease >3, and the presence of visceral metastases. When treatment was added to this final model of significant prognostic factors, there was no treatment effect for overall survival. Again, there was a similar survival between the 2 arms. The adjusted HR for overall survival was 0.99 with 95% CI of 0.79 to 1.23 and Wald P = 0.93.
long-term progression-free survival
At the time of our initial analysis, 334 patients had progressed or died (GC 171, MVAC 163) giving a censoring rate of 17.5%. In this updated report, 362 patients have progressed or died (GC 184, MVAC 178) giving a censoring rate of 10.6%. Progressionfree survival (PFS) was similar in the two arms (HR 1.09; 95% CI 0.89 to1.34, log rank P = 0.4072) as shown in Fig. 2 . The median PFS was 7.7 months with GC (95% CI 6.8 to 8.8 months) and 8.3 months with MVAC (95% CI 7.3 to 9.7 months). Progression-free survival at 24 months, 48 months, and 60 months was 13.9%, 9.8%, and 9.8%, respectively on GC and 18.4%, 12.8%, and 11.3%, respectively on MVAC (Table 4) . A multivariate analysis of all significant prognostic factors was conducted using backward selection to determine the final model for PFS. Independent prognostic factors adversely affecting PFS were poor performance status (<70), raised alkaline phosphatase, measurable disease, presence of visceral metastases, TNM staging (M 1 ), and number of sites of disease >3 (Table 3) . When treatment was added to this final model of significant prognostic factors, there was no treatment effect for PFS. Again, there was a similar PFS in the two arms. The adjusted HR for PFS was 1.01 with 95% CI of 0.81 to 1.25 and Wald P = 0.94.
discussion
Long-term survival of patients with advanced bladder cancer is relatively rare although this disease is chemosensitive. We report on the 5-year survival of patients with advanced or metastatic bladder cancer comparing GC with MVAC in a large, international, multicenter phase III study. This study confirms the results of the earlier analysis: GC provides similar efficacy with regard to overall survival, PFS, and response compared to MVAC in this but does so with a superior safety profile [6] . These long-term results continue to support GC as a standard of care in patients with locally advanced and metastatic bladder cancer. Stadler et al. analyzed long term survival in the three initial and previously published phase II bladder cancer trials [9] [10] [11] [12] in which patients were treated with gemcitabine and cisplatin. The overall median survival of 121 patients was 13.2 months and the estimated 4 year survival was 13% ± 6%. These figures are comparable to those observed in this larger phase III study directly comparing GC and MVAC and further support the effectiveness of the GC regimen in patients with locally advanced and metastatic TCC.
The results of our univariate analysis support the findings of Bajorin et al. who defined KPS, stage and presence or absence of visceral metastases as important, independent prognostic variables [13] . In our study, elevated alkaline phosphatase was also of adverse prognostic significance, in accordance with the study by Sengelov et al. [14] , as was the presence of more than three disease sites. When treatment was added in the final multiple regression model, the hazard ratio for overall survival (HR=0.99) and progression-free survival (HR=1.01) indicated identical efficacy of both treatment regimens. This phase III study was not designed as an equivalence trial, however, the long-term overall survival results demonstrate the very similar efficacy of the GC and MVAC regimens in patients with locally advanced and metastatic bladder cancer. Subgroup analysis of relevant prognostic factors failed to show any differences between the GC and MVAC-treated patients. Similarly, patients with and without liver metastases demonstrated nearly identical overall and progression-free survival on the two different regimens (data not shown). In summary, the increasing acceptance and use of GC in patients with locally advanced and metastatic bladder cancer is supported by its similar clinical efficacy to MVAC. The similar 5-year survival data together with the better tolerability and safety profile of the GC combination to support and strengthen the conclusion [6] that the GC regimen is a safe and effective alternative to MVAC therapy in this patient population. However, given the small number of patients alive after five years, more effective treatments need to be developed to improve the survival of patients with inoperable locally advanced and metastatic urothelial cancer. 
